CION Ameerpet
Cervical Cancer Types · Reviewed by CION Oncologists · NABH Accredited
Squamous Cell Carcinoma of the Cervix — What Your Report Means
If your histopathology report says squamous cell carcinoma, you are reading the commonest diagnosis in cervical cancer — roughly seven in ten cervical cancers worldwide are of this type, according to the WHO classification of female genital tumours. It begins in the flat, tile-like squamous cells that cover the outer surface of the cervix, almost always after years of persistent high-risk HPV infection. That is the type cervical screening was designed around, and the type with the longest and deepest body of treatment evidence behind it. This page explains what the words on your report mean, what the pathologist is measuring, and how the stage — not the type — decides what happens next.
- The commonest type — around seven in ten cervical cancers are squamous cell carcinoma (WHO classification)
- Stage drives treatment — FIGO stage, tumour size and node status matter far more than the histological label
- Well studied and treatable — both surgery and chemoradiation have decades of evidence in this histology
- Tumour board first — every diagnosis is reviewed by surgical, radiation and medical oncology before a plan is offered
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What “Squamous Cell Carcinoma” Means on a Cervical Report
The cervix is lined by two different kinds of cell. The outer surface, facing the vagina, is covered by squamous cells — flat and layered, like tiles. The canal leading up into the womb is lined by glandular cells, which make mucus. Where the two meet there is a border called the transformation zone, and that border is where high-risk HPV most readily takes hold. A squamous cell carcinoma is a cancer that has arisen from the flat cells on that outer surface.
Two words in the diagnosis carry the weight. Squamous tells you which cell the tumour came from. Carcinoma tells you the pathologist has seen tumour cells break through the basement membrane and push into the tissue underneath — in other words, this is invasive cancer, not the precancerous change a screening test picks up. If your earlier reports mentioned CIN, dysplasia or carcinoma in situ, those described abnormal cells that had not yet crossed that line. This report says they have.
That distinction matters because it changes who looks after you and what happens next, but it does not by itself tell you how serious the situation is. A tumour invading three millimetres and one invading three centimetres both read as “invasive squamous cell carcinoma”. The measurements further down the report are what separate them. If you have not yet read how the tissue was obtained and what a pathologist does with it, our guide to the cervical biopsy and what your results mean covers that ground in detail.
Did You Know? The 2020 WHO classification changed how squamous cervical cancer is named. Rather than relying on descriptive subtypes alone, tumours are now divided into HPV-associated and HPV-independent squamous cell carcinoma, with p16 immunohistochemistry used as the surrogate marker for HPV involvement. The overwhelming majority of cervical squamous carcinomas are HPV-associated — which is precisely why a vaccine and a screening test can prevent this cancer at all. Source: WHO Classification of Tumours, Female Genital Tumours, 5th edition (2020).
The Subtypes a Pathologist May Name
These descriptive labels tell your oncologist how the tumour looks down the microscope. With a small number of exceptions they do not change the treatment pathway, which is set by stage.
Common
Non-Keratinizing SCC
Tumour cells that resemble squamous cells but do not produce the tough protein keratin. This is one of the two patterns most often reported in cervical squamous carcinoma, and it behaves the same way as the keratinizing form at equivalent stage.
Common
Keratinizing SCC
The cells make keratin, which the pathologist sees as whorled “keratin pearls” and as individual cells with a horny appearance. It is a description of maturity, not of aggression — stage remains the driver of prognosis.
Uncommon
Basaloid SCC
Nests of small, immature-looking cells with very little cytoplasm. It is usually strongly HPV-associated, and it is generally treated exactly as other squamous carcinomas of the same stage are treated.
Uncommon
Papillary & Warty SCC
Tumours that grow in finger-like fronds, or that carry the cellular changes of HPV infection prominently. A superficial biopsy can under-call these, so a larger sample is sometimes needed before invasion can be confirmed.
Rare
Verrucous Carcinoma
A rare, very well differentiated, warty-looking tumour that grows by pushing rather than by infiltrating. It rarely involves lymph nodes, and surgery is usually preferred where the tumour can be removed completely.
Rare, important
HPV-Independent SCC
A small group of squamous carcinomas that are p16-negative and not driven by HPV. They are recognised separately in the WHO classification because they are not preventable by vaccination and are not reliably detected by HPV-based screening.
If your report names a subtype you cannot find here, bring it to your appointment. Naming conventions differ between laboratories, and the safest interpretation is the one made with the slides in front of a specialist.
The Other Measurements on Your Report — and Why They Matter
Beyond the type, the pathologist records a set of measurements your oncologist will use to choose between surgery and radiation, and to judge whether further treatment is needed after an operation. These are the ones worth understanding:
- Grade (G1, G2, G3) — how closely the tumour cells still resemble normal squamous cells. G1 is well differentiated, G3 poorly differentiated. Grade is one input among several and, in cervical cancer, a weaker predictor than stage or node status.
- Depth of invasion and horizontal extent — measured in millimetres. In very early disease these two measurements alone decide the FIGO sub-stage, and they can be the difference between a fertility-sparing operation and a radical one.
- Lymphovascular space invasion (LVSI) — whether tumour cells are seen inside small lymph channels or blood vessels. Its presence raises the chance that lymph nodes are involved and often influences whether radiation is added after surgery.
- Margin status — on a LEEP or cone specimen, whether abnormal tissue reaches the cut edge. An involved margin usually means more tissue has to be removed, or further treatment given.
- p16 and HPV testing — used to establish whether the tumour is HPV-associated. This is a classification tool rather than a treatment decision in itself.
- Lymph node status — from imaging, or from nodes removed at surgery. Under the FIGO 2018 revision, proven nodal involvement makes the cancer stage IIIC regardless of how small the primary tumour is.
A note on second opinions. Separating squamous carcinoma from cervical adenocarcinoma, and both from a mixed tumour, occasionally needs additional stains and an experienced eye. Where that distinction would genuinely change the plan, CION arranges review of the original slides and paraffin blocks before treatment starts — not afterwards.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Diagnosis Is Not Yet a Plan
Between the biopsy result and the first treatment there is a staging step, and it decides almost everything. Bring your report to any of CION's 7 NABH-accredited Hyderabad locations and we will tell you what still needs to be established.
How Squamous Cell Cervical Cancer Is Staged
Staging answers a single question: how far has the tumour travelled? FIGO revised the cervical staging system in 2018 so that imaging and pathology findings could be used alongside clinical examination, and so that lymph node involvement was recognised in the stage itself. In practice, staging at CION means an examination, an MRI of the pelvis and, in most cases, a PET-CT.
Stage I — confined to the cervix
The tumour is limited to the cervix. The earliest sub-stages are defined purely by millimetre measurements on the biopsy specimen; the later ones by the size of the tumour on imaging. Treatment is usually surgical, and in carefully selected very early tumours an operation that preserves the womb may be possible.
Stage II — beyond the cervix, not to the pelvic wall
The tumour has extended into the upper vagina or into the tissue beside the cervix. Depending on the sub-stage and the tumour size, treatment is either surgery or chemoradiation, and the tumour board weighs which route avoids giving two intensive treatments where one would have done.
Stage III — lower vagina, pelvic wall, kidney drainage, or lymph nodes
This stage covers spread to the lower third of the vagina or to the pelvic side wall, blockage of the tube draining a kidney, and — under the 2018 revision — involvement of pelvic or para-aortic lymph nodes, classified as stage IIIC. Treatment is chemoradiation followed by brachytherapy, the internal radiation step that is essential to cure at this stage.
Stage IV — bladder, rectum or distant organs
The tumour has invaded the lining of the bladder or rectum, or has spread to distant sites. Treatment becomes systemic, often with radiation used to control specific problem areas, and the goals shift towards disease control and quality of life. Those options are set out in full on our cervical cancer treatment in Hyderabad page.
Whatever the number turns out to be, the purpose of staging is to avoid over-treating disease that is contained and under-treating disease that is not. That is why NCCN and ESMO both recommend the plan be set by a multidisciplinary team rather than by whichever specialist you happen to see first.
Squamous Cell Carcinoma Compared With Cervical Adenocarcinoma
Women often want to know whether they have the “better” type. At the same stage the differences are smaller than the internet suggests — but they are real, and they are worth understanding.
| Squamous cell carcinoma | Adenocarcinoma | |
|---|---|---|
| Cell of origin | Flat squamous cells of the outer cervix and transformation zone | Mucus-producing glandular cells lining the cervical canal |
| Share of cervical cancers | The large majority — roughly seven in ten | Most of the remainder, and the proportion has been rising |
| HPV type most often involved | HPV 16 predominates | HPV 18 features more prominently than it does in squamous tumours |
| Detection by cytology | Well suited to Pap-based screening; the precursor lesions sit on the surface | Harder to sample, because the abnormality sits higher in the canal |
| Staging system | Identical — both use FIGO 2018 for cervical cancer | |
| Core treatment approach | Identical in principle — surgery for early stage, chemoradiation with brachytherapy for locally advanced disease | |
| Where the type does matter | The benchmark histology in most cervical cancer trials | Some subtypes behave differently, so pathology review carries more weight |
Tumours containing both cell types are reported separately — see adenosquamous and mixed cervical cancers. For the wider picture of how cervical cancer develops and is prevented, start with the cervical cancer overview.
Did You Know? The 2018 FIGO revision made two changes that directly affect women with squamous cervical cancer. Imaging and pathological findings may now be used to assign the stage, rather than clinical examination alone; and lymph node involvement was given its own category, stage IIIC. That is why an MRI and a PET-CT are arranged before treatment starts — a small cervical tumour with an involved node is a different disease from the same tumour without one. Sources: FIGO 2018 staging for carcinoma of the cervix uteri; NCCN Guidelines for Cervical Cancer.
What Treatment Usually Looks Like for This Type
Squamous cell carcinoma is treated in the same way as other cervical carcinomas of equivalent stage, and the choices divide fairly cleanly:
Early stage — surgery, or radiation where surgery is unsuitable
Removal of the cervix and the surrounding tissue, with assessment of the pelvic lymph nodes. In very small tumours a cone biopsy or an operation that preserves the womb may be an option for a woman who wants to keep the possibility of pregnancy. If the specimen shows involved margins, positive nodes or extensive lymphovascular invasion, treatment after surgery is usually recommended.
Locally advanced — chemoradiation plus brachytherapy
External radiation to the pelvis given alongside platinum-based chemotherapy, followed by brachytherapy, in which the radiation source is placed against the tumour itself. NCCN, FIGO and ESMO guidance all treat brachytherapy as a non-negotiable component of curative treatment at this stage; omitting it measurably reduces the chance of cure.
Advanced or recurrent — systemic treatment, guided by testing
Chemotherapy remains the backbone, with targeted therapy and checkpoint immunotherapy considered depending on what testing of the tumour shows, including PD-L1 status. Radiation is often used alongside to control specific symptoms. The regimens themselves are chosen individually and are discussed on the treatment page rather than here.
Across cervical cancers treated at CION, 1-year survival is 83.3% compared with a national figure of 67.3%. That difference reflects stage at presentation and access to complete treatment — particularly finishing brachytherapy on schedule — more than it reflects any single piece of technology.
Why Women Bring a Cervical Cancer Diagnosis to CION
The weeks between a biopsy result and the first treatment are the ones that shape everything after. They should be organised, not improvised.
Tumour board for every diagnosis
Pathology review before treatment
MRI, PET-CT and biopsy under one roof
Brachytherapy planned from day one
45-minute detailed consultation
Woman doctor available on request
7 NABH-accredited Hyderabad locations
EMI facility & insurance accepted
4.8 / 5 Google rating
Take The Next Step
Understand Your Report Before You Decide Anything
You do not have to commit to a hospital to have your pathology explained properly. Bring the report, ask everything, and decide afterwards.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Squamous Cell Cervical Cancer — Frequently Asked Questions
What does squamous cell carcinoma mean on my cervical biopsy report?
It means the pathologist has confirmed an invasive cancer arising from the flat squamous cells that cover the outer cervix. The word carcinoma is the important one: it says tumour cells have crossed the basement membrane into the tissue below, which distinguishes it from CIN or carcinoma in situ, where abnormal cells are still confined to the surface layer. Squamous cell carcinoma is the commonest type of cervical cancer. The diagnosis alone does not tell you how advanced the disease is — the depth of invasion, tumour size, lymphovascular invasion and lymph node status recorded elsewhere on the report, together with your staging scans, are what determine that.
Is squamous cell cervical cancer more serious than adenocarcinoma?
Neither type should be thought of as the good one or the bad one. At the same FIGO stage the two are staged identically and treated on the same principles, and outcomes are broadly comparable. The practical differences lie elsewhere: squamous carcinoma is the type conventional Pap-based screening detects most reliably, while glandular abnormalities sit higher in the cervical canal and are harder to sample, which is one reason cervical adenocarcinoma is sometimes found later. What actually predicts outcome is stage at diagnosis, tumour size, lymph node involvement, and whether the full course of treatment is completed on schedule.
What does the grade on my squamous cell carcinoma report mean?
Grade describes how closely the tumour cells still resemble normal squamous cells under the microscope. Grade 1 is well differentiated, meaning the cells still look fairly normal; grade 3 is poorly differentiated, meaning they have largely lost that resemblance. It is a useful descriptive marker, but in cervical cancer grade is a considerably weaker predictor than stage, tumour size or lymph node status, and on its own it rarely changes the treatment pathway. If your report shows a high grade alongside lymphovascular invasion, that combination may influence whether treatment is recommended after surgery — a question for your oncologist with the full report in hand.
Does squamous cell cervical cancer show up on a Pap smear?
Cervical screening is designed to find the precancerous squamous changes that precede this cancer, and it does that well, because those abnormalities sit on the outer surface of the cervix where the sampling brush reaches. That is why squamous carcinoma is the type most reliably prevented by regular screening. A Pap smear is a screening test, however, not a diagnostic one. It can read as normal in the presence of an established tumour, particularly if the sample was inadequate or the tumour bled heavily. A diagnosis is only made by taking tissue at colposcopy and biopsy and examining it under the microscope.
What is lymphovascular space invasion and why does it matter?
Lymphovascular space invasion, usually shortened to LVSI, means the pathologist has seen tumour cells inside the small lymph channels or blood vessels within the tissue. It does not mean the cancer has already spread. What it indicates is that the tumour has found a route by which spread could occur, and its presence is associated with a higher chance that pelvic lymph nodes are involved. For that reason LVSI is one of the factors weighed when deciding whether radiation should be added after surgery, and it is one of the details a tumour board looks at closely when the primary tumour itself appears small.
Medical disclaimer: This page is general health information, reviewed by a CION oncologist. It is not a diagnosis, a stage or a treatment recommendation, and it cannot replace review of your own pathology and imaging by a specialist. Please discuss your report with your treating team before making any decision about treatment.